eligibility_summary
Inclusion: consent, ≥18, ECOG 0–1, life expectancy >3 mo, contraception, women of childbearing potential: negative pregnancy test, not lactating, able to comply, Part 1: histologic/cytologic advanced/metastatic solid tumors after SOC failure or none. Exclusion: ≥2 malignancies in past 5 yrs, recent anti-cancer/investigational therapy (chemo <3 wks, others <4 wks, nitrosourea/mitomycin <6 wks, targeted/FP <5 half-lives, TCM <2 wks), active brain mets/LM, treated stable brain mets ≥4 wks off steroids ≥14 d allowed, prior same target, unresolved ≥G2 AEs.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study: Phase I/II, single-arm trial of MHB036C in advanced solid tumors. Drug/intervention and mechanism: MHB036C is an intravenous antibody–drug conjugate (ADC) dosed every 3 weeks. It consists of a tumor antigen–targeting monoclonal antibody linked to a cytotoxic payload. After binding to the antigen on tumor cells, the complex is internalized, linker cleavage releases the payload to kill tumor cells (typically via microtubule disruption and/or DNA damage). Fc-mediated immune effector functions may contribute. Cells/pathways targeted: Tumor cells expressing the (unspecified) target antigen. Key pathways include antigen-mediated endocytosis/lysosomal processing and apoptosis pathways activated by the released payload. Trial aims: Determine safety/MTD (Phase I) and efficacy/RP2D (Phase II). Status: Active, not recruiting (China).